Skip to main content


Marketed Products

Two innovative therapies utilizing Kala’s proprietary AMPPLIFY® Drug Delivery Technology to address medical needs for front of the eye

EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%

First and only prescription therapy specifically for the short-term management
of the signs and symptoms of dry eye disease

Inveltys (loteprednol etabonate ophthalmic suspension) 1% THERE IS NO GENERIC EQUIVALENT

First and only BID corticosteroid indicated for the treatment of post-operative ocular inflammation and pain

Development Pipeline

Proprietary development programs targeted to address front and back of the eye diseases

Product Candidate* Classification Preclinical Phase 1 Phase 2 Phase 3
Stem Cell (MSC) Secretome
Persistent Corneal Epithelial Defect (PCED)(Phase 1)
KPI-287: Tyrosine Kinase Inhibitor
Retinal diseases, including wet AMD, DME, and RVO (Preclinical)
Selective Glucocorticoid
Receptor Modulator (SEGRM)
Retinal diseases, including wet AMD, DME, and RVO;
ocular surface diseases

*Product candidates are investigational and have not been approved by any regulatory authority.

NCE – New Chemical Entity

Please review our Privacy Statement(opens new window). This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement(opens new window) .